USPTO serial 79074243
MTM
Reviewed by CopyMark Law Group
Reg. 3818640Status 404
- Filing date
- Status date
- Registration date
- Jul 13, 2010
- Examiner
- HOLTZ, ALLISON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with MTM?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
JAMES R. CADY
JAMES R. CADY HOWREY LLP1950 UNIVERSITY AVENUE, 4TH FLOOREAST PALO ALTO, CA 94303UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science, diagnostic preparations, reagents and chemical test kits comprised of reagents for chemical analyses and reagents for medical research use for detection of cancerous conditions, neoplastic conditions, inflammatory conditions, infectious conditions, degenerative conditions, genetically aberrant or diseased conditions, proliferatively aberrant or diseased conditions, vascular disease conditions, premalignant conditions, malignant conditions, cancer and inborn errors for scientific or research use | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations for the treatment and prevention of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases and for the treatment of premalignant and malignant cancerous conditions, cancer and inborn errors; veterinary preparations for the treatment and prevention of neoplastic, inflammatory, infectious, degenerative, genetic and proliferative and vascular diseases and for the treatment of premalignant and malignant cancerous conditions, cancer and inborn errors in livestock, cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats, mice, rats, monkeys, apes and birds; medical diagnostic reagents and kits comprised of medical diagnostic reagents and assays for detection of cancer and neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases and for the detection of premalignant and malignant cancerous conditions, cancer and inborn errors; medical diagnostic preparations, namely, in-vitro and in-vivo diagnostic test kits, diagnostic immunocytochemical kits, diagnostic immunohistochemical kits, diagnostic histology kits, diagnostic cytology kits, diagnostic liquid-immuno-assay kits, diagnostic solid-phase immuno-assay kits, diagnostic strip-tests, diagnostic dip-stick-tests, point of care tests, diagnostic lateral-flow assay kits, diagnostic flow-through assay kits, diagnostic immuno-chromatographic kits, all of the above-mentioned kits being for use in early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative or vascular diseases | SECTION 71 - CANCELLED | — |
| 010 | Medical diagnostic testing machines, namely, point-of-care testing machines, diagnostic liquid-immuno-assay machines, diagnostic immunocytochemical machines, diagnostic immunohistochemical machines, diagnostic histology machines, diagnostic cytology machines, diagnostic solid-phase immuno assay machines, diagnostic ELISA testing machines, diagnostic immuno-chromatographic machines, all of the aforementioned machines being used to analyze and/or provide diagnostic test results and used in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious and genetic diseases associated with cancer, proliferative diseases associated with neoplastics and dysplastic conditions or vascular diseases as indicated above; medical diagnostic equipment, namely, containers specially designed for storing and transporting medical samples in the nature of tubes, multiwell plates, columns, strips, sticks and brushes, and medical syringes, needles for medical use, spatulas for medical samples and medical diagnostic testing, and medical diagnostic testing swabs, cloths and tampons, all for use in sampling, storing, transporting, preparing, enriching, concentrating, testing, analyzing and evaluating biological material and samples in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative and vascular diseases as indicated above; medical diagnostic nucleic acid detection machines, medical diagnostic nucleic acid amplification machines, medical diagnostic immuno-histology machines and medical diagnostic immuno-cytology machines all used to analyze and/or provide diagnostic test results and used in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification or therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious and genetic diseases associated with cancer, proliferative diseases associated with neoplastics and dysplastic conditions or vascular diseases as indicated above; medical diagnostic apparatuses and instruments, namely, hand-held, table-top and floor-standing centrifugal, gravitational-separating, electrophoretic, chromatographic, conductometric, potentiometric, spectrometric, spectro-photometric, radiologic electromagnetic-resonance, histological, microscopic and in-vivo-imaging machines and apparatuses for use in preparing, enriching, concentrating, testing, analyzing and evaluating of biological material and samples in connection with early diagnosis, prognosis, grading, monitoring, staging, predictive therapy guidance, patient stratification and therapy guidance of premalignant and malignant conditions, cancer, inborn errors and infectious, genetic, proliferative and vascular diseases as indicated above for clinical and medical laboratory use | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services and research and design relating thereto in the fields of chemistry, biology, molecular biology, pharmaceutics, and pharmacogenomics; industrial analysis and research services in the fields of chemistry, biology, molecular biology, pharmaceutics, and pharmacogenomics, design and development of computer hardware and software, scientific analysis in the fields of chemistry, biology and molecular biology, laboratory research in the field of molecular biology; laboratory research in the fields of pharmaceutics and food technology; providing research in the fields of pharmaceutical, chemical and diagnostic research; research and development of pharmaceutical products and substances for others; scientific research in the nature of scientific information research services; chemical, biological, molecular biology and pharmacogenomic analysis services | SECTION 71 - CANCELLED | — |
| 044 | Medical services, veterinary services, medical diagnostic services and provision of medical diagnostic information in the field of detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn errors; veterinary diagnostic services and provision of veterinary diagnostic information in the field of detection of neoplastic, inflammatory, infectious, degenerative, genetic, proliferative and vascular diseases, premalignant and malignant cancerous conditions, cancer and inborn errors in livestock, cattle, pigs, horses, deer, elk, moose, sheep, dogs, cats, mice, rats, monkeys, apes and birds | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MTM Laboratories AG
- Other trademarks owned by MTM Laboratories AG
- Other trademarks owned by Roche mtm laboratories AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named MTM
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 6, 2020 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Mar 6, 2020 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Nov 17, 2017 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Oct 19, 2017 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Oct 19, 2017 | INPC | INVALIDATION PROCESSED | — |
| Oct 17, 2017 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Feb 17, 2017 | C71T | CANCELLED SECTION 71 | — |
| Feb 13, 2013 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 2, 2012 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Oct 22, 2010 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 22, 2010 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Oct 14, 2010 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jul 13, 2010 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Apr 27, 2010 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 27, 2010 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 22, 2010 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Mar 18, 2010 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 4, 2010 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Feb 22, 2010 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Feb 22, 2010 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 22, 2010 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 22, 2010 | ALIE | ASSIGNED TO LIE | — |
| Jan 22, 2010 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jan 22, 2010 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 25, 2009 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 1, 2009 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 1, 2009 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 1, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 30, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 27, 2009 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Nov 26, 2009 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 25, 2009 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 21, 2009 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Nov 17, 2009 | DOCK | ASSIGNED TO EXAMINER | — |
| Nov 17, 2009 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Nov 12, 2009 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |